首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 再生醫學細胞療法基因療法

市場調查報告書

商品編碼

2107883

抗體偶聯T受體療法市場：依適應症和地區分類

Anti-body Coupled T Receptor Therapy Market, By Indication (Lymphoma, Breast Cancer, Neuroblastoma, Other Indications), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

出版日期: 2026年07月23日 | 出版商:

Coherent Market Insights | 英文 258 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

抗體偶聯T受體療法市場預計在2026年達到5,500萬美元，預計2033年將達到1.126億美元。預計從2026年到2033年，該市場將以10.8%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	5500萬美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	10.80%	2033年市場規模預測：	1.126億美元

由於癌症發病率上升、標靶免疫療法的廣泛應用、細胞和基因療法研究投資的增加以及 T 細胞工程技術的不斷進步，預計市場將經歷顯著成長。

抗體偶聯T細胞受體（ACTR）療法是一種新型的過繼性T細胞免疫療法，它將基因改造的T細胞與標靶腫瘤的抗體結合，以識別並摧毀癌細胞。此療法首先對患者來源的T細胞進行改造，使其表達抗體偶聯的T細胞受體（ACTR），然後在實驗室中培養，最後與識別特定腫瘤靶點的單株抗體一起重新輸注給患者。這樣，經過改造的T細胞就能選擇性地攻擊抗體標記的癌細胞，同時可能減少對健康組織的傷害。

與傳統細胞療法相比，ACTR療法具有多項優勢，包括治療柔軟性、更廣泛的標靶化能力，以及能夠將不同的腫瘤標靶抗體整合到相同基因修飾的T細胞平台上。骨髓惡性腫瘤（如淋巴瘤、乳癌和神經母細胞瘤）以及固體癌領域研究活動的活性化，正在推動基於ACTR的療法的發展。此外，對精準腫瘤學和個人化癌症治療的日益重視，預計將在預測期內創造新的市場成長機會。

此外，臨床試驗的增加、策略聯盟的建立以及抗體工程、基因編輯和細胞製造流程等方面的技術進步，進一步推動了市場成長。製藥和生技公司正投資研發下一代T細胞療法，以提高治療的安全性、有效性和擴充性。對具有更優標標靶化機制的先進癌症療法的需求不斷成長，預計將進一步加速抗體偶聯T受體療法在全球的應用。

市場動態

抗體偶聯 T 受體療法市場的發展動力來自癌症發病率的上升、免疫療法的進步以及對細胞和基因療法研發投入的增加。

成長要素之一是全球癌症負擔的日益加重。隨著骨髓惡性腫瘤和固體癌發生率的上升，人們對能夠為復發性或抗藥性癌症患者帶來更好治療效果的先進標靶治療的需求日益成長。世界衛生組織（WHO）預測，到2050年，全球癌症患者人數預計將成長約77%，每年新增病例將超過3,500萬例。這種日益加重的疾病負擔預計將推動對創新免疫療法的需求，包括抗體偶聯T受體（ACTR）療法。

推動市場成長的另一個主要因素是精準腫瘤學和個人化醫療方法的日益普及。 ACTR療法利用腫瘤特異性抗體誘導基因修飾的T細胞進入癌細胞，從而實現標靶癌症治療。與傳統療法相比，這種方法具有更大的治療柔軟性，目前正在針對多種癌症適應症進行研究，包括淋巴瘤、乳癌和神經母細胞瘤。

對細胞和基因療法研發投入的增加也促進了市場擴張。生物技術和製藥公司正在加強臨床開發活動，建立策略聯盟，並投資先進的製造技術，以加速下一代T細胞療法的開發。例如，2025年10月，JW Therapeutics和Regeneron Pharmaceuticals擴大了策略聯盟，以推進TCR-T細胞療法的開發並支持癌症免疫療法的創新。

基因編輯、抗體工程、次世代定序(NGS)、基於人工智慧的藥物發現以及細胞製造過程的進步，進一步提升了ACTR療法的開發潛力。這些進步可望提高治療精準度、增強安全性，並提高基因修飾T細胞療法的規模化應用能力。

然而，抗體偶聯T受體療法（ACTR）市場面臨許多挑戰，例如研發成本高昂、生產過程複雜、監管要求嚴格以及缺乏專業的細胞治療基礎設施。此外，由於ACTR療法屬於個人化治療，因此需要先進的生產能力和熟練的專業人員，這可能會限制其在某些地區的推廣應用。

儘管面臨這些挑戰，但在預測期內，在活性化、固體癌應用範圍擴大、免疫療法平台投資增加以及生物技術公司與研究機構之間合作加強的推動下，預計將出現顯著的成長機會。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
本研究深入分析了市場促進因素、限制因素、機會、新興趨勢、臨床發展趨勢、區域前景以及領先企業採取的競爭策略。
本研究基於公司亮點、產品系列、臨床開發、合作關係和策略，分析了抗體偶聯 T 受體療法市場的主要參與者。
透過利用本報告中提出的見解，製藥公司、生技公司、投資者、研究人員和醫療保健機構可以就產品開發、臨床投資和策略合作夥伴關係做出明智的決策。
《抗體偶聯 T 受體療法市場》報告的目標受群眾外包括細胞療法開發商、生物技術公司、製藥製造商、腫瘤研究人員、醫療保健提供者、投資者、監管機構和金融相關人員等各類利益相關者。
相關人員可以利用用於評估抗體偶聯 T 受體療法市場的系統分析框架和策略矩陣，從中獲益匪淺。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第6章競爭情勢

公司簡介
- Unum Therapeutics
- Pfizer Inc.
- Novartis AG
- Johnson and Johnson Services, Inc.
- GSK plc
- The Bristol-Myers Squibb Company
- Others

第7章

參考
調查方法

簡介目錄

Product Code: CMI1600

Anti-body Coupled T Receptor Therapy Market is estimated to be valued at USD 55.0 Mn in 2026 and is expected to reach USD 112.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 10.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 55.0 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	10.80%	2033 Value Projection:	USD 112.6 Mn

The market is projected to witness significant growth due to the rising prevalence of cancer, increasing adoption of targeted immunotherapies, growing investments in cell and gene therapy research, and continuous advancements in T-cell engineering technologies.

Anti-body coupled T receptor (ACTR) therapy is an emerging adoptive T-cell immunotherapy that uses genetically engineered T cells combined with tumor-targeting antibodies to identify and destroy cancer cells. In this approach, patient-derived T cells are modified to express an antibody-coupled T-cell receptor (ACTR), expanded in the laboratory, and infused back into the patient along with monoclonal antibodies that recognize specific cancer targets. This enables engineered T cells to selectively attack antibody-tagged tumor cells while potentially reducing damage to healthy tissues.

ACTR therapy offers several advantages compared with conventional cell therapies, including treatment flexibility, broader targeting capability, and the ability to use the same engineered T-cell platform with different tumor-targeting antibodies. Increasing research activities in hematological malignancies and solid tumors, including lymphoma, breast cancer, and neuroblastoma, are supporting the development of ACTR-based therapies. In addition, rising focus on precision oncology and personalized cancer treatments is expected to create new opportunities for market growth during the forecast period.

The market growth is further supported by increasing clinical trials, strategic collaborations, and technological advancements in antibody engineering, gene editing, and cell manufacturing processes. Pharmaceutical and biotechnology companies are investing in next-generation T-cell therapies to improve treatment safety, efficacy, and scalability. Growing demand for advanced cancer therapies with improved targeting mechanisms is expected to strengthen the adoption of antibody-coupled T receptor therapies worldwide.

Market Dynamics

The Anti-body Coupled T Receptor Therapy Market is driven by increasing cancer incidence, advancements in immunotherapy, and rising investments in cell and gene therapy development.

One of the primary growth drivers is the increasing global cancer burden. Rising incidence of hematological malignancies and solid tumors is increasing demand for advanced targeted therapies that can provide improved treatment outcomes for patients with relapsed or treatment-resistant cancers. According to the World Health Organization (WHO), global cancer cases are projected to increase by approximately 77% by 2050, reaching more than 35 Mn new cases annually. This growing disease burden is expected to support demand for innovative immunotherapies, including ACTR-based treatments.

Another major factor supporting market growth is the increasing adoption of precision oncology and personalized medicine approaches. ACTR therapy enables targeted cancer treatment by using tumor-specific antibodies to guide engineered T cells toward cancer cells. This approach provides greater treatment flexibility compared with conventional therapies and is being investigated for multiple cancer indications, including lymphoma, breast cancer, and neuroblastoma.

Growing investments in cell and gene therapy research are also contributing to market expansion. Biotechnology and pharmaceutical companies are increasing clinical development activities, forming strategic partnerships, and investing in advanced manufacturing technologies to accelerate the development of next-generation T-cell therapies. For example, in October 2025, JW Therapeutics and Regeneron Pharmaceuticals, Inc. expanded their strategic collaboration to advance TCR-T cell therapy development, supporting innovation in cancer immunotherapy.

Technological advancements in gene editing, antibody engineering, next-generation sequencing (NGS), artificial intelligence-assisted drug discovery, and cell manufacturing processes are further improving the development potential of ACTR therapies. These advancements are expected to enhance treatment precision, improve safety profiles, and increase the scalability of engineered T-cell therapies.

However, the Anti-body Coupled T Receptor Therapy Market faces challenges including high development costs, complex manufacturing processes, regulatory requirements, and limited availability of specialized cell therapy infrastructure. The personalized nature of ACTR therapies also requires advanced manufacturing capabilities and skilled professionals, which may limit adoption in some regions.

Despite these challenges, increasing clinical research activities, expanding applications in solid tumors, rising investments in immunotherapy platforms, and growing collaborations between biotechnology companies and research institutions are expected to create significant growth opportunities during the forecast period.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study provides key insights about market drivers, restraints, opportunities, emerging trends, clinical developments, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the Anti-body Coupled T Receptor Therapy Market based on company highlights, product portfolio, clinical developments, partnerships, and strategies.
Key companies covered as part of this study include Unum Therapeutics, Pfizer Inc., Novartis AG, Johnson and Johnson Services, Inc., GSK plc, The Bristol-Myers Squibb Company, and others.
Insights from this report would allow pharmaceutical companies, biotechnology firms, investors, researchers, and healthcare organizations to make informed decisions regarding product development, clinical investments, and strategic partnerships.
The Anti-body Coupled T Receptor Therapy Market report caters to various stakeholders including cell therapy developers, biotechnology companies, pharmaceutical manufacturers, oncology researchers, healthcare providers, investors, regulatory authorities, and financial analysts.
Stakeholders would benefit from structured analytical frameworks and strategy matrices used in evaluating the Anti-body Coupled T Receptor Therapy Market.

Market Segmentation

By Indication Insights (Revenue, USD Mn, 2021 - 2033)
Lymphoma
Breast Cancer
Neuroblastoma
Other Indications
By Region Insights (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players
Unum Therapeutics
Pfizer Inc.
Novartis AG
Johnson and Johnson Services, Inc.
GSK plc
The Bristol-Myers Squibb Company
Others

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Indication
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Market Opportunities
Impact Analysis
Market Trends
Recent Indication Launches/Approvals
Regulatory Scenario
Epidemiology
PEST Analysis
Acquisition and Collaboration Scenario

4. Global Anti-body Coupled T Receptor Therapy Market, By Indication, 2021 - 2033 (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Neuroblastoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)

5. Global Anti-body Coupled T Receptor Therapy Market, By Region, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2021 - 2033
- Regional Trends
North America
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - U.S.
  - Canada
Europe
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - China
  - Japan
  - India
  - ASEAN
  - Australia
  - South Korea
  - Rest of APAC
Latin America
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - North Africa
  - Central Africa
  - South Africa

6. Competitive Landscape

Company Profiles
- Unum Therapeutics
  - Company Overview
  - Indication Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Indication Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Novartis AG
  - Company Overview
  - Indication Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Johnson and Johnson Services, Inc.
  - Company Overview
  - Indication Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- GSK plc
  - Company Overview
  - Indication Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- The Bristol-Myers Squibb Company
  - Company Overview
  - Indication Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Others
  - Company Overview
  - Indication Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies